Repironics buys out UK distributor
This article was originally published in Clinica
Executive Summary
US company Respironics is to acquire its UK distributor of 15 years, Profile Therapeutics. The Murrysville, Pennsylvania company agreed to buy all outstanding shares of Profile, at a price of 50.9p ($0.93) per share. The total value of the transaction is estimated at $46m. The combined annual revenues of the two companies add up to approximately $745m.